Quarterly report pursuant to Section 13 or 15(d)

Debt - Narrative (Details)

v3.7.0.1
Debt - Narrative (Details)
3 Months Ended 48 Months Ended
Mar. 17, 2017
USD ($)
Nov. 05, 2015
USD ($)
Apr. 01, 2015
d
conversion_right
$ / shares
Jan. 30, 2013
USD ($)
d
$ / shares
Mar. 31, 2017
USD ($)
institution
$ / shares
Dec. 31, 2016
USD ($)
institution
shares
Debt Instrument [Line Items]            
Gain on embedded derivative         $ 4,900,000  
Credit line capacity         190,717,000  
Goodwill         $ 705,990,000 $ 704,603,000
Number of financial institutions | institution         10 10
BioReference            
Debt Instrument [Line Items]            
Net assets         $ 1,000,000,000  
Goodwill         401,800,000  
Intangible assets         $ 478,100,000  
OPKO Health Europe            
Debt Instrument [Line Items]            
Weighted average interest rate         3.00% 3.20%
Minimum | OPKO Health Europe            
Debt Instrument [Line Items]            
Variable interest rates         1.80%  
Maximum | OPKO Health Europe            
Debt Instrument [Line Items]            
Variable interest rates         6.30%  
Notes            
Debt Instrument [Line Items]            
Long-term debt         $ 39,285,000 $ 43,701,000
Notes | Notes Due February 1, 2033            
Debt Instrument [Line Items]            
Debt face amount       $ 175,000,000.0    
Interest rate on notes payable       3.00%    
Equivalent redemption price       100.00%    
Conversion price per share (in dollars per share) | $ / shares     $ 7.07 $ 7.07 $ 7.07  
Convertible debt, threshold percentage of stock price trigger     130.00% 130.00%    
Number of trading days | d     20      
Conversion rate     0.1414827 0.14148 0.1414827  
Number of consecutive trading days applicable conversion price     30 days      
Conversion right triggered | conversion_right     1      
Common stock trigger price (in dollars per share) | $ / shares     $ 9.19      
Long-term debt         $ 31,900,000  
Notes | Notes Due February 1, 2033 | Minimum            
Debt Instrument [Line Items]            
Number of trading days | d       20    
Notes | Notes Due February 1, 2033 | Maximum            
Debt Instrument [Line Items]            
Number of consecutive trading days applicable conversion price       30 days    
Notes | Notes Due February 1, 2033 | On or after February 1, 2017 and before February 1, 2019            
Debt Instrument [Line Items]            
Equivalent redemption price       100.00%    
Notes | Notes Due February 1, 2033 | On or after February 1, 2019            
Debt Instrument [Line Items]            
Equivalent redemption price       100.00%    
Convertible Debt | Notes Due February 1, 2033            
Debt Instrument [Line Items]            
Converted debt amount           $ 143,200,000.0
Line of Credit            
Debt Instrument [Line Items]            
Weighted average interest rate         4.20% 4.70%
Revolving Credit Facility | Line of Credit | New Credit Agreement            
Debt Instrument [Line Items]            
Credit line capacity   $ 175,000,000.0        
Higher borrowing capacity option   $ 275,000,000.0        
Commitment fee percentage   0.25%        
Maximum intercompany loan $ 55,000,000          
Swingline | Line of Credit | New Credit Agreement            
Debt Instrument [Line Items]            
Credit line capacity   $ 20,000,000.0        
Letter of Credit | Line of Credit | New Credit Agreement            
Debt Instrument [Line Items]            
Credit line capacity   $ 20,000,000.0        
LIBOR | Revolving Credit Facility | Line of Credit | New Credit Agreement            
Debt Instrument [Line Items]            
Basis spread on variable rate   2.50%        
LIBOR, First 12 Months | Revolving Credit Facility | Line of Credit | New Credit Agreement            
Debt Instrument [Line Items]            
Basis spread on variable rate   0.35%        
LIBOR Thereafter | Revolving Credit Facility | Line of Credit | New Credit Agreement            
Debt Instrument [Line Items]            
Basis spread on variable rate   0.50%        
LIBOR, First 12 Months, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement            
Debt Instrument [Line Items]            
Basis spread on variable rate   1.35%        
LIBOR, Thereafter, Adjusted for Eurocurrency Liabilities | Revolving Credit Facility | Line of Credit | New Credit Agreement            
Debt Instrument [Line Items]            
Basis spread on variable rate   1.50%        
Common Stock | Convertible Debt | Notes Due February 1, 2033            
Debt Instrument [Line Items]            
Shares issued on converted debt (in shares) | shares           21,539,873